NRIX Stock: Insider Activity, Filings & Research

Nurix Therapeutics, Inc. (NRIX) — Drillr’s hub for NRIX insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, NRIX insiders filed 0 open-market buys and 9 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$868.1K

Insider trades by month Buys Sells

Jan

Feb

Mar

Apr

May

Jun

Context3-month price -4.8%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
Jun 2, 2026	Ring Christineofficer: Chief Legal Officer	Option	3,422	$1.86
Jun 2, 2026	Ring Christineofficer: Chief Legal Officer	Sell	8,148	$16.60
May 15, 2026	Baynes Roy D.director	Grant	31,250	$15.86
May 15, 2026	Silva Paul Mdirector	Grant	31,250	$15.86
May 15, 2026	Kapur Anildirector	Grant	31,250	$15.86
May 15, 2026	DANSEY ROGER Ddirector	Grant	31,250	$15.86
May 15, 2026	Reinsdorf Judith Adirector	Grant	31,250	$15.86
May 15, 2026	Saltzman Edward Cdirector	Grant	31,250	$15.86
May 15, 2026	Lacey David L.director	Grant	31,250	$15.86
May 15, 2026	GREGORY JULIA Pdirector	Grant	31,250	$15.86
May 5, 2026	van Houte Hansofficer: Chief Financial Officer	Sell	13,473	$16.58
May 5, 2026	van Houte Hansofficer: Chief Financial Officer	Sell	582	$17.18
May 4, 2026	Ring Christineofficer: Chief Legal Officer	Sell	8,148	$16.96
May 1, 2026	Ring Christineofficer: Chief Legal Officer	Sell	5,394	$16.76
Apr 30, 2026	Ring Christineofficer: Chief Legal Officer	Sell	3,214	$16.65

Source: NRIX SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.

Overview

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a biopharmaceutical company founded in 2009 and headquartered in San Francisco, California. The company went public in July 2020, raising capital to advance its innovative approach to drug discovery and development. Nurix focuses on developing small molecule therapies that leverage targeted protein degradation, a cutting-edge approach in biotechnology that aims to treat cancer and immune disorders by selectively destroying disease-causing proteins within cells.

Business

Nurix operates in the biotechnology sector, specifically in the field of targeted protein degradation, which represents a novel approach to drug development. Traditional drugs typically work by blocking or inhibiting proteins, but Nurix's technology actually destroys problematic proteins entirely, potentially offering more effective treatments with fewer side effects. The company's core technology platform centers around two main mechanisms: protein degraders and protein inhibitors. Protein degraders work by hijacking the cell's natural protein disposal system, called the ubiquitin-proteasome system, to selectively tag and eliminate specific disease-causing proteins. This approach can potentially target proteins that were previously considered "undruggable" with conventional methods. Nurix's pipeline includes several key programs. NX-2127 and NX-5948 are both Bruton's tyrosine kinase (BTK) degraders designed to treat relapsed or refractory B-cell malignancies, which are blood cancers affecting white blood cells. BTK is a protein that plays a crucial role in B-cell development and function, and its overactivity contributes to certain cancers. NX-1607 and NX-0255 target CBL-B, a protein that acts as a brake on the immune system's ability to fight cancer. By inhibiting CBL-B, these drugs aim to enhance the body's natural anti-cancer immune response. The company also develops DeTIL-0255, which is in Phase 1 clinical trials for gynecologic cancers including ovarian, endometrial, and cervical cancers. This represents Nurix's approach to adoptive T-cell therapy, where immune cells are enhanced outside the body before being reintroduced to fight cancer.

Revenue model

Nurix generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, rather than through direct product sales, as its drugs are still in clinical development phases. The company has established significant partnerships with Gilead Sciences and Sanofi, which provide upfront payments, milestone payments, and potential royalties on future drug sales. Recent financial data shows quarterly revenues ranging from $12-18 million, primarily from these collaboration agreements. These partnerships allow Nurix to share development costs and risks while gaining access to the larger companies' resources, regulatory expertise, and global commercialization capabilities. Several factors could significantly impact Nurix's future profitability. Positive clinical trial results would likely trigger milestone payments from partners and increase the company's valuation, while negative results could reduce future revenue streams. The competitive landscape in targeted protein degradation is intensifying, with larger pharmaceutical companies developing their own capabilities in this area. Regulatory approval timelines and requirements also directly affect when the company might begin receiving royalty payments from commercialized products. Additionally, the company's ability to attract new partnerships and expand existing ones will be crucial for maintaining revenue growth during the extended development period typical in biotechnology.

Competitive moat

Nurix's competitive moat is moderately strong but not insurmountable. The company's primary advantage lies in its specialized expertise in targeted protein degradation, a relatively new field where it has built significant intellectual property and know-how. The complexity of this technology creates barriers to entry, as developing effective protein degraders requires deep understanding of cellular biology, protein structure, and the ubiquitin-proteasome system. However, this moat faces several challenges. Large pharmaceutical companies like Roche, Bristol Myers Squibb, and Pfizer are rapidly building their own protein degradation capabilities, either through internal development or acquisitions. These companies have substantially greater resources and can potentially outspend Nurix in research and development. The field is also attracting numerous well-funded startups, creating an increasingly crowded competitive landscape. Nurix's partnerships with Gilead and Sanofi provide some protection by aligning the company with established players, but these relationships also limit the company's independence and potential upside. The ultimate test of Nurix's moat will be whether its specific approach to protein degradation proves superior in clinical trials compared to competitors' methods. Given the early stage of most programs in this field, the competitive dynamics remain fluid and the durability of any technological advantage is uncertain.

Risks & safety

Nurix presents a moderate to high-risk investment profile typical of clinical-stage biotechnology companies, with significant cash reserves but substantial ongoing losses. • Cash position: $76 million in cash and short-term investments as of Q1 2025, down from $110 million in Q4 2024, indicating rapid cash consumption • Cash burn: Free cash flow of -$65 million in Q1 2025, suggesting approximately 1.2 years of runway at current burn rate • Debt levels: Very low debt-to-equity ratio of 0.055, indicating minimal financial leverage risk • Liquidity: Strong current ratio of 6.26, with current assets significantly exceeding current liabilities • Valuation: Trading at negative P/E ratios due to losses, but Graham net-net value of 4.97 suggests potential asset value • Solvency risk: Low immediate risk due to strong balance sheet, but will likely need additional funding within 12-18 months to continue operations

Recent development

Based on the company's financial trajectory over recent years, Nurix has been executing a strategy focused on advancing its clinical pipeline while building strategic partnerships. The company's revenue has fluctuated significantly, ranging from $39 million in 2022 to $77 million in 2023, then declining to $55 million in 2024, reflecting the milestone-driven nature of partnership agreements. The company has been investing heavily in research and development, with operating cash flow losses consistently exceeding $150 million annually. This substantial investment reflects the company's focus on advancing multiple clinical programs simultaneously, including moving NX-2127 and NX-5948 through clinical trials for B-cell malignancies and developing its CBL-B inhibitor programs for immuno-oncology applications. Nurix has strengthened its financial position through its partnerships, particularly with Gilead Sciences, which has provided significant funding to support the company's development programs. The collaboration with Sanofi represents another strategic move to diversify the company's partnership base and reduce dependence on a single major partner. These partnerships not only provide financial resources but also validate the company's technology platform and provide access to larger companies' clinical development expertise.

NRIX company profile · for informational purposes only — not investment advice.

Track NRIX with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free